Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects
Glioma is one of the most intractable types of cancer, due to delayed diagnosis at advanced stages. The clinical symptoms of glioma are unclear and due to a variety of glioma subtypes, available low-invasive testing is not effective enough to be introduced into routine medical laboratory practice. T...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1216102/full |
| _version_ | 1827793289091219456 |
|---|---|
| author | Alina Penkova Olga Kuziakova Valeriia Gulaia Vladlena Tiasto Nikolay V. Goncharov Nikolay V. Goncharov Daria Lanskikh Valeriia Zhmenia Ivan Baklanov Ivan Baklanov Vladislav Farniev Vadim Kumeiko Vadim Kumeiko |
| author_facet | Alina Penkova Olga Kuziakova Valeriia Gulaia Vladlena Tiasto Nikolay V. Goncharov Nikolay V. Goncharov Daria Lanskikh Valeriia Zhmenia Ivan Baklanov Ivan Baklanov Vladislav Farniev Vadim Kumeiko Vadim Kumeiko |
| author_sort | Alina Penkova |
| collection | DOAJ |
| description | Glioma is one of the most intractable types of cancer, due to delayed diagnosis at advanced stages. The clinical symptoms of glioma are unclear and due to a variety of glioma subtypes, available low-invasive testing is not effective enough to be introduced into routine medical laboratory practice. Therefore, recent advances in the clinical diagnosis of glioma have focused on liquid biopsy approaches that utilize a wide range of techniques such as next-generation sequencing (NGS), droplet-digital polymerase chain reaction (ddPCR), and quantitative PCR (qPCR). Among all techniques, NGS is the most advantageous diagnostic method. Despite the rapid cheapening of NGS experiments, the cost of such diagnostics remains high. Moreover, high-throughput diagnostics are not appropriate for molecular profiling of gliomas since patients with gliomas exhibit only a few diagnostic markers. In this review, we highlighted all available assays for glioma diagnosing for main pathogenic glioma DNA sequence alterations. In the present study, we reviewed the possibility of integrating routine molecular methods into the diagnosis of gliomas. We state that the development of an affordable assay covering all glioma genetic aberrations could enable early detection and improve patient outcomes. Moreover, the development of such molecular diagnostic kits could potentially be a good alternative to expensive NGS-based approaches. |
| first_indexed | 2024-03-11T18:16:25Z |
| format | Article |
| id | doaj.art-a22b0620d80a4903a2f69381e714666e |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-03-11T18:16:25Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-a22b0620d80a4903a2f69381e714666e2023-10-16T07:24:24ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2023-10-011010.3389/fmolb.2023.12161021216102Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospectsAlina Penkova0Olga Kuziakova1Valeriia Gulaia2Vladlena Tiasto3Nikolay V. Goncharov4Nikolay V. Goncharov5Daria Lanskikh6Valeriia Zhmenia7Ivan Baklanov8Ivan Baklanov9Vladislav Farniev10Vadim Kumeiko11Vadim Kumeiko12Institute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaA. V. Zhirmunsky National Scientific Center of Marine Biology, FEB RAS, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaA. V. Zhirmunsky National Scientific Center of Marine Biology, FEB RAS, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaInstitute of Life Sciences and Biomedicine, Far Eastern Federal University, Vladivostok, RussiaA. V. Zhirmunsky National Scientific Center of Marine Biology, FEB RAS, Vladivostok, RussiaGlioma is one of the most intractable types of cancer, due to delayed diagnosis at advanced stages. The clinical symptoms of glioma are unclear and due to a variety of glioma subtypes, available low-invasive testing is not effective enough to be introduced into routine medical laboratory practice. Therefore, recent advances in the clinical diagnosis of glioma have focused on liquid biopsy approaches that utilize a wide range of techniques such as next-generation sequencing (NGS), droplet-digital polymerase chain reaction (ddPCR), and quantitative PCR (qPCR). Among all techniques, NGS is the most advantageous diagnostic method. Despite the rapid cheapening of NGS experiments, the cost of such diagnostics remains high. Moreover, high-throughput diagnostics are not appropriate for molecular profiling of gliomas since patients with gliomas exhibit only a few diagnostic markers. In this review, we highlighted all available assays for glioma diagnosing for main pathogenic glioma DNA sequence alterations. In the present study, we reviewed the possibility of integrating routine molecular methods into the diagnosis of gliomas. We state that the development of an affordable assay covering all glioma genetic aberrations could enable early detection and improve patient outcomes. Moreover, the development of such molecular diagnostic kits could potentially be a good alternative to expensive NGS-based approaches.https://www.frontiersin.org/articles/10.3389/fmolb.2023.1216102/fullcancer molecular diagnosticsNGS panelPCRmolecular markers of gliomamedical market |
| spellingShingle | Alina Penkova Olga Kuziakova Valeriia Gulaia Vladlena Tiasto Nikolay V. Goncharov Nikolay V. Goncharov Daria Lanskikh Valeriia Zhmenia Ivan Baklanov Ivan Baklanov Vladislav Farniev Vadim Kumeiko Vadim Kumeiko Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects Frontiers in Molecular Biosciences cancer molecular diagnostics NGS panel PCR molecular markers of glioma medical market |
| title | Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects |
| title_full | Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects |
| title_fullStr | Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects |
| title_full_unstemmed | Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects |
| title_short | Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects |
| title_sort | comprehensive clinical assays for molecular diagnostics of gliomas the current state and future prospects |
| topic | cancer molecular diagnostics NGS panel PCR molecular markers of glioma medical market |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1216102/full |
| work_keys_str_mv | AT alinapenkova comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT olgakuziakova comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT valeriiagulaia comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT vladlenatiasto comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT nikolayvgoncharov comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT nikolayvgoncharov comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT darialanskikh comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT valeriiazhmenia comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT ivanbaklanov comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT ivanbaklanov comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT vladislavfarniev comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT vadimkumeiko comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects AT vadimkumeiko comprehensiveclinicalassaysformoleculardiagnosticsofgliomasthecurrentstateandfutureprospects |